Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Unusualness of Hep C Market Not Being Understood, Gilead COO Says on Possible Sovaldi Re-Pricing
December 4, 2015
-
REGULATORY Probe Finds Kaketsuken’s GMP Violations “Extremely Malicious”, MHLW to Impose Penalty
December 3, 2015
-
REGULATORY NHI-Market Price Gap at 8.8%, 6.8% Price Cut Expected in FY2016 Revision
December 3, 2015
-
REGULATORY MHLW Discussing Use of Disease Registry as Substitute for Control Groups; Could Be “One Means of Evaluation” in Trials for Rare Diseases
December 2, 2015
-
BUSINESS Mitsubishi Tanabe Set to Derive 40% of Sales Abroad in FY2020, Shed 1,200 Jobs over 5 Years
December 1, 2015
-
BUSINESS Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
-
TRENDS AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
-
REGULATORY Evaluation of Efficacy Was Challenging in Sakigake Pick, Designating All Qualified Drugs Desirable: MHLW Official
November 27, 2015
-
REGULATORY Drug Pricing Debate to Culminate in December; Abraxane, Zosyn Major Candidates for Market Expansion Re-Pricing
November 26, 2015
-
REGULATORY Don’t Seek Near-Term Profits but Have Long-Term Vision, MHLW Official Tells Drug Makers
November 25, 2015
-
REGULATORY MHLW Eyes Using HTA to Re-Price Drugs with Big Sales Outlooks That Have Gone Through 1 or 2 Price Revisions
November 24, 2015
-
ACADEMIA Viekirax Joins Fray in Hep C Market, Can It Crack into Harvoni’s Stronghold?
November 20, 2015
-
ORGANIZATION Industry Wants OTC Tax Break and No Annual Price Cuts, Groups Tell LDP
November 19, 2015
-
REGULATORY AbbVie’s Hep C Drug Viekirax Priced at 53,000 Yen Daily vs. Harvoni’s 80,000 Yen
November 18, 2015
-
BUSINESS Generic Makers’ Earnings Show Unabated Momentum 1 Year after Medical Fee Reform: Tally
November 17, 2015
-
BUSINESS AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
-
REGULATORY Business Improvement Order Issued to Novartis Japan
November 13, 2015
-
REGULATORY Chuikyo Subcommittee Broadly OKs Price Maintenance Rule for Essential Drugs
November 12, 2015
-
BUSINESS Top 4 Wholesalers See 7% Sales Rise on Hep C Drugs, but Paltry 0.82% in Operating Margin
November 11, 2015
-
REGULATORY Novartis Fails to Report Nearly 5,500 Side Effect Cases, Biz Improvement Order Likely This Month
November 10, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…